These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23430741)

  • 21. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design.
    Saha P; Bhattacharyya S; Kesavardhana S; Miranda ER; Ali PS; Sharma D; Varadarajan R
    Biochemistry; 2012 Mar; 51(9):1836-47. PubMed ID: 22329717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.
    Visciano ML; Tuen M; Gorny MK; Hioe CE
    Virology; 2008 Mar; 372(2):409-20. PubMed ID: 18054978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
    Chen L; Kwon YD; Zhou T; Wu X; O'Dell S; Cavacini L; Hessell AJ; Pancera M; Tang M; Xu L; Yang ZY; Zhang MY; Arthos J; Burton DR; Dimitrov DS; Nabel GJ; Posner MR; Sodroski J; Wyatt R; Mascola JR; Kwong PD
    Science; 2009 Nov; 326(5956):1123-7. PubMed ID: 19965434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
    J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
    Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
    Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
    Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
    J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
    J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing antigenicity and immunogenicity of engineered gp120.
    Selvarajah S; Puffer B; Pantophlet R; Law M; Doms RW; Burton DR
    J Virol; 2005 Oct; 79(19):12148-63. PubMed ID: 16160142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.
    Narayan KM; Agrawal N; Du SX; Muranaka JE; Bauer K; Leaman DP; Phung P; Limoli K; Chen H; Boenig RI; Wrin T; Zwick MB; Whalen RG
    PLoS One; 2013; 8(1):e52732. PubMed ID: 23326351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
    Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
    Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.